NASDAQ: OKUR
Onkure Therapeutics Inc Stock Ownership - Who owns Onkure Therapeutics?

Insider buying vs selling

Have Onkure Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Nicholas A. SaccomanoCEO;Pres2026-09-2187$2.97
$258.74Sell
Jason A. LeveroneCFO2026-09-21302$2.97
$898.15Sell
Nicholas A. SaccomanoPresident and CEO2026-06-2286$4.40
$378.06Sell
Jason A. LeveroneChief Financial Officer2026-06-22303$4.40
$1.33kSell
Jason A. LeveroneChief Financial Officer2026-03-23301$4.16
$1.25kSell
Nicholas A. SaccomanoPresident and CEO2026-03-2386$4.16
$357.50Sell
Nicholas A. SaccomanoPresident and CEO2025-12-2287$2.97
$258.22Sell
Jason A. LeveroneChief Financial Officer2025-12-22302$2.97
$896.34Sell

1 of 1

OKUR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OKUR insiders and whales buy or sell their stock.

OKUR Shareholders

What type of owners hold Onkure Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
New Enterprise Associates 15 LP11.82%4,785,494$12.54MInsider
Ai Biotechnology LLC9.87%3,998,332$10.48MInsider
Braden Michael Leonard9.64%3,905,210$10.23MInsider
Holdings A. Novo8.22%3,330,337$8.73MInsider
Acorn Bioventures LP7.01%2,839,674$7.44MInsider
Rivervest Venture Fund III LP5.95%2,409,220$6.31MInsider
Niall Odonnell5.40%2,188,713$5.73MInsider
Bali Muralidhar5.12%2,073,957$5.43MInsider
Cormorant Asset Management LP4.48%1,813,439$4.75MInsider
Acorn Bioventures 2 LP2.79%1,129,730$2.96MInsider

1 of 3

OKUR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OKUR0.09%72.59%Net SellingNet Selling
VYGR0.06%48.15%Net Selling
UNCY0.04%16.43%
ANIX0.02%79.04%Net BuyingNet Buying
PYPD0.02%0.02%

Onkure Therapeutics Stock Ownership FAQ

Who owns Onkure Therapeutics?

Onkure Therapeutics (NASDAQ: OKUR) is owned by 0.09% institutional shareholders, 72.59% Onkure Therapeutics insiders, and 27.33% retail investors. New Enterprise Associates 15 LP is the largest individual Onkure Therapeutics shareholder, owning 4.79M shares representing 11.82% of the company. New Enterprise Associates 15 LP's Onkure Therapeutics shares are currently valued at $12.54M.

If you're new to stock investing, here's how to buy Onkure Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.